TLDR
- VKTX climbs as VK2735 shows strong weight loss and metabolic health gains.
- New VK2735 data boosts VKTX momentum with major improvements in prediabetes.
- VK2735 Phase 2 results demonstrate notable weight and cardiometabolic progress.
- VKTX advances VK2735 after data show strong metabolic and weight loss effects.
- VK2735 delivers promising obesity outcomes, supporting VKTX’s pipeline strength.
Viking Therapeutics, Inc. (VKTX) shares climbed nearly 3% today, closing around $37.52 amid strong trading volumes.
Viking Therapeutics, Inc., VKTX
The price rise followed new clinical data released at ObesityWeek® 2025, showcasing VK2735’s effectiveness in treating metabolic conditions. The upward trend suggests renewed short-term confidence in VKTX and its leading obesity drug candidate.
VK2735 Shows Strong Glycemic Improvement in Prediabetic Patients
VKTX presented new data on VK2735 at ObesityWeek® 2025, highlighting its dual action on GLP-1 and GIP receptors. The subcutaneous formulation demonstrated strong effects in prediabetic patients during a 13-week Phase 2 VENTURE clinical trial. This formulation of VK2735 improved glycemic status in 78% of prediabetic patients, far surpassing the placebo group’s 29%.
The exploratory analysis assessed changes in glycemic control and metabolic syndrome (MetS) prevalence among participants. VK2735 significantly reduced the number of patients with prediabetes and MetS by the study’s end. These results emphasize VK2735’s role in managing early metabolic disorders and potentially preventing diabetes progression.
The clinical data support VK2735’s ability to address more than just weight reduction. VKTX aims to position VK2735 as a full-spectrum cardiometabolic solution. Continued improvements in glycemic markers show potential beyond traditional weight-loss therapies.
Phase 2 Data Confirm Substantial and Progressive Weight Loss
In the Phase 2 VENTURE study, VK2735 achieved meaningful reductions in mean body weight over the 13-week period. Patients recorded up to 14.7% body weight loss, with results emerging as early as Week One. VKTX confirmed statistically significant weight loss at all dosages throughout the study.
More than 88% of patients in VK2735 groups achieved at least 10% weight loss, compared to only 4% in the placebo group. These consistent improvements continued without signs of plateauing by the final week of treatment. VKTX views this trend as a strong signal of the drug’s sustained efficacy.
In addition to weight loss, the study reaffirmed safety and tolerability across treatment arms. Over 90% of treatment-related adverse events were mild or moderate. VKTX emphasized that safety remains a critical component of VK2735’s clinical profile.
Phase 3 Study Aims to Broaden Clinical Validation
VKTX also introduced details on its ongoing Phase 3 VANQUISH-1 trial at ObesityWeek. This study targets overweight and obese adults with at least one weight-related condition. The trial’s primary endpoint will measure total body weight change over time.
The VANQUISH-1 design includes additional endpoints focusing on physical function, mental health, and productivity. These criteria reflect a broader evaluation of VK2735’s potential health benefits. VKTX expects this trial to validate VK2735’s utility beyond weight loss alone.
Enrollment is ongoing, and results will likely influence the company’s future regulatory strategy. VKTX continues to prioritize clinical advancement across both subcutaneous and oral VK2735 programs. Positive outcomes from VANQUISH-1 could further strengthen market positioning for VK2735.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
